Your browser is no longer supported. Please, upgrade your browser.
Settings
OMED OncoMed Pharmaceuticals, Inc. daily Stock Chart
OMED [NASD]
OncoMed Pharmaceuticals, Inc.
Index- P/E7.15 EPS (ttm)0.13 Insider Own0.70% Shs Outstand40.20M Perf Week-20.51%
Market Cap37.39M Forward P/E- EPS next Y-0.95 Insider Trans-4.71% Shs Float32.02M Perf Month-45.61%
Income4.90M PEG- EPS next Q-0.22 Inst Own64.90% Short Float1.04% Perf Quarter-62.50%
Sales54.90M P/S0.68 EPS this Y66.00% Inst Trans-1.63% Short Ratio1.75 Perf Half Y-67.48%
Book/sh1.34 P/B0.69 EPS next Y-206.50% ROA6.50% Target Price1.50 Perf Year-81.29%
Cash/sh1.76 P/C0.53 EPS next 5Y- ROE25.80% 52W Range0.87 - 5.19 Perf YTD-77.32%
Dividend- P/FCF- EPS past 5Y45.00% ROI84.30% 52W High-82.08% Beta1.57
Dividend %- Quick Ratio3.40 Sales past 5Y9.10% Gross Margin- 52W Low6.88% ATR0.14
Employees56 Current Ratio3.40 Sales Q/Q282.40% Oper. Margin5.70% RSI (14)26.33 Volatility13.17% 10.07%
OptionableYes Debt/Eq0.00 EPS Q/Q155.90% Profit Margin11.00% Rel Volume5.20 Prev Close0.98
ShortableYes LT Debt/Eq0.00 EarningsNov 01 Payout0.00% Avg Volume190.63K Price0.93
Recom3.00 SMA20-30.42% SMA50-47.33% SMA200-62.24% Volume990,691 Change-5.11%
May-15-17Reiterated H.C. Wainwright Buy $9 → $6
Apr-17-17Downgrade SunTrust Buy → Hold
Apr-17-17Downgrade Piper Jaffray Overweight → Neutral
Apr-11-17Reiterated H.C. Wainwright Buy $20 → $9
Dec-20-16Initiated SunTrust Buy $16
Sep-22-16Initiated H.C. Wainwright Buy $20
May-26-16Reiterated Mizuho Buy $15 → $16
Jan-26-16Reiterated Mizuho Buy $40 → $15
Jan-25-16Downgrade Leerink Partners Outperform → Mkt Perform
Jan-06-16Reiterated Mizuho Neutral $45 → $40
Dec-04-15Initiated Wells Fargo Outperform
Sep-09-15Initiated Jefferies Buy
Jun-13-14Reiterated Mizuho Buy
Feb-11-14Initiated Mizuho Buy $45
Dec-07-18 08:04AM  The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut Benzinga
Dec-05-18 04:32PM  This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger American City Business Journals
08:10AM  Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals GlobeNewswire
Nov-15-18 08:40AM  Recent Analysis Shows Construction Partners, OptimizeRx, OncoMed Pharmaceuticals, Issuer Direct, Red Violet, and Golden Minerals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-09-18 08:00AM  OncoMed Announces Early Clinical Data for anti-TIGIT Antibody GlobeNewswire -6.47%
Nov-05-18 03:02PM  OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Delivered A Weaker ROE Than Its Industry Simply Wall St.
Nov-01-18 06:42PM  OncoMed: 3Q Earnings Snapshot Associated Press +7.93%
04:05PM  OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
Oct-22-18 08:00AM  OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer GlobeNewswire -6.67%
Oct-20-18 06:30AM  OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer GlobeNewswire
Oct-09-18 08:00AM  OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting GlobeNewswire
Sep-24-18 04:00PM  OncoMed to Present at the Cantor Global Healthcare Conference GlobeNewswire
08:00AM  OncoMed Announces Publication of Phase 1a Data of Navicixizumab GlobeNewswire
Sep-20-18 08:00AM  OncoMed Provides Update on Navicixizumab Partnership GlobeNewswire -14.29%
Sep-12-18 03:08PM  Can OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improve Your Portfolio Returns? Simply Wall St.
Aug-29-18 04:00PM  OncoMed to Present at Two Upcoming Investor Conferences in September GlobeNewswire +6.22%
Aug-02-18 10:25AM  OncoMed Pharmaceuticals (OMED) Reports Q2 Loss, Misses Revenue Estimates Zacks
09:17AM  OncoMed: 2Q Earnings Snapshot Associated Press
08:00AM  OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
Jun-12-18 08:00AM  OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial GlobeNewswire
May-08-18 06:59PM  OncoMed: 1Q Earnings Snapshot Associated Press
04:05PM  OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights GlobeNewswire
May-03-18 11:39AM  Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y Zacks
May-01-18 07:30AM  OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018 GlobeNewswire +7.07%
Apr-30-18 11:56AM  Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y Zacks
Apr-19-18 09:35AM  3 Biotech Stocks That Will Thrive Amid Market Instability InvestorPlace
Apr-18-18 09:01AM  OncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting GlobeNewswire -6.79%
Apr-09-18 08:30AM  OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-27-18 12:01PM  Can The Uptrend Continue for OncoMed Pharmaceuticals (OMED)? Zacks
Mar-19-18 08:32AM  OncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of Directors GlobeNewswire
Mar-16-18 12:22PM  OncoMed Pharmaceuticals Inc (NASDAQ:OMED): What Are The Future Prospects? Simply Wall St.
Mar-14-18 02:58PM  Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now Insider Monkey
Mar-09-18 04:06PM  Edited Transcript of OMED earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents +6.82%
Mar-08-18 06:51PM  When Can We Expect A Profit From OncoMed Pharmaceuticals Inc (NASDAQ:OMED)? Simply Wall St. +6.94%
04:37PM  OncoMed tops Street 4Q forecasts Associated Press
04:15PM  OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights GlobeNewswire
12:00PM  OncoMed Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
09:36AM  OncoMed Pharmaceuticals Q4 Earnings Preview Benzinga
Mar-07-18 03:55PM  Has OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improved Earnings Growth In Recent Times? Simply Wall St.
Feb-22-18 04:02PM  OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018 GlobeNewswire
Feb-21-18 06:18AM  Why You Need To Look At This Factor Before Buying OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Simply Wall St.
Feb-15-18 11:02AM  Best-In-Class Growth Stocks Simply Wall St.
Jan-29-18 07:22PM  Whats Installed For OncoMed Pharmaceuticals Inc (NASDAQ:OMED)? Simply Wall St. -7.37%
Jan-10-18 05:42PM  What Should You Know About OncoMed Pharmaceuticals Incs (NASDAQ:OMED) Earnings Trajectory? Simply Wall St.
Jan-08-18 02:13PM  Newman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. - OMED Business Wire -12.01%
Jan-05-18 04:50PM  Outspoken biotech CEO Paul Hastings leaves Peninsula company (Video) American City Business Journals
Jan-04-18 04:02PM  OncoMed Provides 2018 Outlook and 2017 Year-End Cash Balance and Announces an Update on the Rosmantuzumab Program GlobeNewswire
04:02PM  OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings has Resigned GlobeNewswire
Dec-19-17 05:35AM  [$$] 5 Biotech Stocks a Pro Is Buying Barrons.com
Dec-15-17 06:15PM  Who Owns Most Of OncoMed Pharmaceuticals Inc (NASDAQ:OMED)? Simply Wall St.
Nov-27-17 04:05PM  OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman Responsibilities GlobeNewswire
Nov-13-17 01:45PM  What You Must Know About OncoMed Pharmaceuticals Incs (OMED) Risks Simply Wall St.
Nov-08-17 06:26PM  ETFs with exposure to OncoMed Pharmaceuticals, Inc. : November 8, 2017 Capital Cube -8.37%
Nov-07-17 08:16AM  OncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube
Nov-05-17 08:16PM  Edited Transcript of OMED earnings conference call or presentation 2-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
Nov-02-17 06:54PM  OncoMed reports 3Q loss Associated Press
04:05PM  OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights GlobeNewswire
10:30AM  OncoMed Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-27-17 07:01PM  OncoMed Pharmaceuticals Inc (OMED): Is Now The Time To Bet On Healthcare? Simply Wall St. +6.21%
Oct-24-17 04:30PM  OncoMed Pharmaceuticals to Report Third Quarter Financial Results and Operational Highlights on November 2nd, 2017 GlobeNewswire
Sep-28-17 01:50PM  What You Must Know About OncoMed Pharmaceuticals Incs (OMED) Risks Simply Wall St.
Sep-19-17 08:30AM  OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence GlobeNewswire
Sep-13-17 08:05AM  OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial GlobeNewswire
Aug-31-17 07:53PM  ETFs with exposure to OncoMed Pharmaceuticals, Inc. : August 31, 2017 Capital Cube
Aug-25-17 10:49AM  OncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
Aug-12-17 01:46AM  Edited Transcript of OMED earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-03-17 09:01PM  ETFs with exposure to OncoMed Pharmaceuticals, Inc. : August 4, 2017 Capital Cube +21.10%
Aug-02-17 04:05PM  OncoMed Announces Second Quarter 2017 Financial Results GlobeNewswire
11:00AM  Investor Network: OncoMed Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-26-17 04:25PM  OncoMed Pharmaceuticals to Report Second Quarter Financial Results on August 2nd, 2017 GlobeNewswire
Jul-12-17 02:51PM  ETFs with exposure to OncoMed Pharmaceuticals, Inc. : July 12, 2017 Capital Cube
Jun-16-17 04:09PM  ETFs with exposure to OncoMed Pharmaceuticals, Inc. : June 16, 2017 Capital Cube
Jun-05-17 02:37PM  ETFs with exposure to OncoMed Pharmaceuticals, Inc. : June 5, 2017 Capital Cube
Jun-02-17 10:15AM  OncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube +5.76%
May-15-17 09:00PM  Newman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. Business Wire
May-12-17 11:10PM  Edited Transcript of OMED earnings conference call or presentation 8-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-11-17 06:55AM  Human Antibody Discovery: Of Mice And Phage Forbes
May-09-17 12:16PM  Strike three: Peninsula biotech swings, misses on third cancer drug trial in past month American City Business Journals
May-08-17 04:20PM  Strike three: Peninsula biotech swings, misses on third cancer drug trial in past month American City Business Journals
07:15AM  OncoMed Pharma stock drops 17% after clinical trial miss; Q1 revenue miss MarketWatch
07:00AM  Investor Network: OncoMed Pharmaceuticals, Inc. to Host Earnings Call Accesswire
06:56AM  OncoMed reports 1Q loss Associated Press
06:50AM  OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results GlobeNewswire
May-04-17 08:30AM  OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial GlobeNewswire
May-03-17 08:30AM  OncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017 GlobeNewswire -8.88%
05:51AM  [$$] Four Small Biotechs See Bullish April Stock Buys Barrons.com
Apr-24-17 05:34PM  Bay Area biotech slashes half of staff after drug partnerships falter American City Business Journals
04:53PM  OncoMed to lay off half of its staff MarketWatch
04:35PM  OncoMed Announces Workforce Reduction GlobeNewswire
Apr-18-17 06:42PM  Here's Why OncoMed Pharmaceuticals (OMED) Stock Fell Today Zacks
07:59AM  OncoMed is having a no good, very bad week MarketWatch
Apr-17-17 10:43AM  OncoMed's lung cancer drug fails mid-stage study, shares tumble Reuters -17.15%
09:28AM  Biotech Movers: OncoMed, Incyte, Omeros TheStreet.com
08:50AM  OncoMed stock drops 25% after lung cancer drug misses in mid-stage clinical trial MarketWatch
08:23AM  OncoMed's lung cancer drug fails mid-stage study Reuters
08:00AM  OncoMeds Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints GlobeNewswire
Apr-11-17 06:05PM  OncoMed Cancer Candidate Fails Trial, Bayer Opts Out of Deal Zacks -10.81%
09:58AM  Do Any Signs Of Life Remain In OnceMed's Demcizumab Development? Benzinga
Apr-10-17 05:10PM  Peninsula biotech tumbles as cancer trial fails, Bayer nixes drug option American City Business Journals -36.64%
04:40PM  Why OncoMed Pharmaceuticals, AK Steel, and Intrawest Resorts Holdings Slumped Today Motley Fool
OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stagg RobertSVP, Clinical R&DOct 10Sale2.019271,86340,670Oct 11 07:00 PM
Li YvonneSee RemarksOct 10Sale2.029271,87359,734Oct 11 06:59 PM
Gurney AustinSee RemarksOct 10Sale2.011,1562,32477,924Oct 11 06:57 PM
Hager Alicia J.SVP & General CounselOct 10Sale2.021,1562,33551,754Oct 11 06:56 PM
Lewicki John A.President & CEOOct 10Sale2.011,1562,32455,966Oct 11 06:55 PM
Li YvonneSee RemarksOct 09Sale2.131,2292,61660,661Oct 10 07:44 PM
Gurney AustinSee RemarksOct 09Sale2.131,6863,58979,080Oct 10 07:42 PM
Stagg RobertSVP, Clinical R&DOct 09Sale2.131,6863,58941,597Oct 10 07:41 PM
Lewicki John A.President & CEOOct 09Sale2.132,2964,88857,122Oct 10 07:40 PM
Hager Alicia J.SVP & General CounselOct 09Sale2.131,6863,58952,910Oct 10 07:38 PM
Gurney AustinSee RemarksApr 24Sale2.684,05110,84876,766Apr 26 06:12 PM
Lewicki John A.President & CEOApr 24Sale2.684,55712,20255,418Apr 26 06:13 PM
Li YvonneSee RemarksApr 24Sale2.685,06213,55559,890Apr 26 06:14 PM
Hager Alicia J.SVP & General CounselApr 24Sale2.684,05110,84854,596Apr 26 06:11 PM
Stagg RobertSVP, Clinical R&DApr 24Sale2.684,05110,84843,283Apr 26 06:13 PM